Corrupted adipose tissue endogenous myelopoiesis initiates diet-induced metabolic disease

  1. Elodie Luche
  2. Virginie Robert
  3. Vincent Cuminetti
  4. Céline Pomié
  5. Quentin Sastourné-Array
  6. Aurélie Waget
  7. Emmanuelle Arnaud
  8. Audrey Varin
  9. Elodie Labit
  10. Patrick Laharrague
  11. Remy Burcelin
  12. Louis Casteilla
  13. Beatrice Cousin  Is a corresponding author
  1. Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, France
  2. INSERM U1048, France
  3. Université de Toulouse, EFS, INP-ENVT, Inserm U1031, UPS; BP 84225, France
  4. U1048 , France
  5. STROMALab, France

Abstract

Activation and increased numbers of inflammatory macrophages, in adipose tissue (AT) are deleterious in metabolic diseases. Up to now, AT macrophages (ATM) accumulation was considered to be due to blood infiltration or local proliferation, although the presence of resident hematopoietic stem/progenitor cells (Lin-/Sca+/c-Kit+; LSK phenotype) in the AT (AT-LSK) has been reported. By using transplantation of sorted AT-LSK and gain and loss of function studies we show that some of the inflammatory ATM inducing metabolic disease, originate from resident AT-LSK. Transplantation of AT-LSK sorted from high fat diet-fed (HFD) mice is sufficient to induce ATM accumulation, and to transfer metabolic disease in control mice. Conversely, the transplantation of control AT-LSK improves both AT-inflammation and glucose homeostasis in HFD mice. Our results clearly demonstrate that resident AT-LSK are one of the key point of metabolic disease, and could thus constitute a new promising therapeutic target to fight against metabolic disease.

Article and author information

Author details

  1. Elodie Luche

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Virginie Robert

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Vincent Cuminetti

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Céline Pomié

    INSERM U1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Quentin Sastourné-Array

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Aurélie Waget

    INSERM U1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Emmanuelle Arnaud

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Audrey Varin

    STROMALab, Université de Toulouse, EFS, INP-ENVT, Inserm U1031, UPS; BP 84225, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Elodie Labit

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Patrick Laharrague

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Remy Burcelin

    U1048 , Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Louis Casteilla

    STROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Beatrice Cousin

    Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm U1031, STROMALab, Toulouse, France
    For correspondence
    beatrice.cousin@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2952-4601

Funding

Aviesan/AstraZeneca

  • Louis Casteilla
  • Beatrice Cousin

Société Francophone du Diabète

  • Beatrice Cousin

ANR (ANR 16-CE14-0006-01)

  • Beatrice Cousin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Michael Czech, University of Massachusetts Medical School, United States

Ethics

Animal experimentation: Animals were maintained in accordance to guidelines of the European Community Council. All experimental procedures were done in compliance with European regulations for animal experimentation. The authors have received requested approval from their Institutional Ethic Committee, and from Ministry of National Education, Higher Education and Research (# 2691-2015110616015905) for all the experiments performed.

Version history

  1. Received: January 9, 2017
  2. Accepted: June 28, 2017
  3. Accepted Manuscript published: June 28, 2017 (version 1)
  4. Version of Record published: July 13, 2017 (version 2)

Copyright

© 2017, Luche et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,026
    views
  • 207
    downloads
  • 16
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Elodie Luche
  2. Virginie Robert
  3. Vincent Cuminetti
  4. Céline Pomié
  5. Quentin Sastourné-Array
  6. Aurélie Waget
  7. Emmanuelle Arnaud
  8. Audrey Varin
  9. Elodie Labit
  10. Patrick Laharrague
  11. Remy Burcelin
  12. Louis Casteilla
  13. Beatrice Cousin
(2017)
Corrupted adipose tissue endogenous myelopoiesis initiates diet-induced metabolic disease
eLife 6:e23194.
https://doi.org/10.7554/eLife.23194

Share this article

https://doi.org/10.7554/eLife.23194

Further reading

    1. Developmental Biology
    2. Medicine
    Stephen E Flaherty III, Olivier Bezy ... Zhidan Wu
    Research Article

    From a forward mutagenetic screen to discover mutations associated with obesity, we identified mutations in the Spag7 gene linked to metabolic dysfunction in mice. Here, we show that SPAG7 KO mice are born smaller and develop obesity and glucose intolerance in adulthood. This obesity does not stem from hyperphagia, but a decrease in energy expenditure. The KO animals also display reduced exercise tolerance and muscle function due to impaired mitochondrial function. Furthermore, SPAG7-deficiency in developing embryos leads to intrauterine growth restriction, brought on by placental insufficiency, likely due to abnormal development of the placental junctional zone. This insufficiency leads to loss of SPAG7-deficient fetuses in utero and reduced birth weights of those that survive. We hypothesize that a ‘thrifty phenotype’ is ingrained in SPAG7 KO animals during development that leads to adult obesity. Collectively, these results indicate that SPAG7 is essential for embryonic development and energy homeostasis later in life.

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Nikola Sekulovski, Jenna C Wettstein ... Kenichiro Taniguchi
    Research Article

    Amniogenesis, a process critical for continuation of healthy pregnancy, is triggered in a collection of pluripotent epiblast cells as the human embryo implants. Previous studies have established that bone morphogenetic protein (BMP) signaling is a major driver of this lineage specifying process, but the downstream BMP-dependent transcriptional networks that lead to successful amniogenesis remain to be identified. This is, in part, due to the current lack of a robust and reproducible model system that enables mechanistic investigations exclusively into amniogenesis. Here, we developed an improved model of early amnion specification, using a human pluripotent stem cell-based platform in which the activation of BMP signaling is controlled and synchronous. Uniform amniogenesis is seen within 48 hr after BMP activation, and the resulting cells share transcriptomic characteristics with amnion cells of a gastrulating human embryo. Using detailed time-course transcriptomic analyses, we established a previously uncharacterized BMP-dependent amniotic transcriptional cascade, and identified markers that represent five distinct stages of amnion fate specification; the expression of selected markers was validated in early post-implantation macaque embryos. Moreover, a cohort of factors that could potentially control specific stages of amniogenesis was identified, including the transcription factor TFAP2A. Functionally, we determined that, once amniogenesis is triggered by the BMP pathway, TFAP2A controls the progression of amniogenesis. This work presents a temporally resolved transcriptomic resource for several previously uncharacterized amniogenesis states and demonstrates a critical intermediate role for TFAP2A during amnion fate specification.